Neonatology
Research Briefings
NIV NAVA versus Nasal CPAP in Premature Infants: A Randomized Clinical TrialKallio M.a,b · Mahlman M.a,b,c · Koskela U.a,b · Aikio O.a,b · Suo-Palosaari M.d,e · Pokka T.a,b · Saarela T.a,b · Hallman M.a,baPEDEGO Research Unit, Medical Research Center Oulu, University of Oulu, Oulu, Finland
bDepartment of Children and Adolescents, Oulu University Hospital, Oulu, Finland cChildren’s Hospital, Pediatric Research Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland dResearch Unit of Medical Imaging, Physics and Technology, Department of Diagnostic Radiology, Faculty of Medicine, University of Oulu, Oulu, Finland eMedical Research Center, Oulu University Hospital, University of Oulu, Oulu, Finland |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: May 14, 2019
Accepted: July 24, 2019
Published online: September 05, 2019
Issue release date: November 2019
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2
ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)
For additional information: https://www.karger.com/NEO
Abstract
Background: Noninvasive ventilation is recommended for neonatal respiratory distress to avoid adverse effects of invasive ventilation. Objective: The aim of this study was to compare the feasibility of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and continuous positive airway pressure (CPAP) in preterm newborn infants. Methods: Forty preterm infants (gestational age 28+0 to 36+6 weeks) requiring CPAP and supplemental oxygen (FiO2 >0.23) for respiratory distress at <48 h of postnatal age were randomized to NIV NAVA or CPAP. The primary endpoint was the inspired oxygen concentration 12 h after study inclusion. Secondary endpoints were the duration of oxygen treatment, total duration of respiratory support, parenteral nutrition, blood gas values, patient comfort, need for invasive ventilation, and treatment complications. Results: The mean FiO2 at the time of study inclusion was 0.29 in both groups. After 12 h of treatment, FiO2 was 0.26 ± 0.07 and 0.26 ± 0.04 in the NIV NAVA and CPAP groups, respectively (difference 0.006, 95% CI –0.4 to 0.5), with no difference between the groups during the course of noninvasive ventilation (p = 0.80). Seven patients (35%) in the NIV NAVA group and 10 (50%) in the control group required intubation (difference 15%, 95% CI –15.5 to 4.3, p = 0.36). Time to intubation, gas exchange, vital parameters, pain scale, treatment complications, and neonatal outcome did not differ between the groups. Conclusions: In the present trial, NIV NAVA had no statistically significant effect on oxygen requirements or the need for invasive ventilation in preterm newborn infants.
© 2019 S. Karger AG, Basel
Related Articles:
References
- Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019;115(4):432–50.
- Huang L, Mendler MR, Waitz M, Schmid M, Hassan MA, Hummler HD. Effects of Synchronization during Noninvasive Intermittent Mandatory Ventilation in Preterm Infants with Respiratory Distress Syndrome Immediately after Extubation. Neonatology. 2015;108(2):108–14.
- Stein H, Alosh H, Ethington P, White DB. Prospective crossover comparison between NAVA and pressure control ventilation in premature neonates less than 1500 grams. J Perinatol. 2013 Jun;33(6):452–6.
- Lee J, Kim HS, Jung YH, Shin SH, Choi CW, Kim EK, et al. Non-invasive neurally adjusted ventilatory assist in preterm infants: a randomised phase II crossover trial. Arch Dis Child Fetal Neonatal Ed. 2015 Nov;100(6):F507–13.
- Colaizy TT, Kummet GJ, Kummet CM, Klein JM. Noninvasive Neurally Adjusted Ventilatory Assist in Premature Infants Postextubation. Am J Perinatol. 2017 May;34(6):593–8.
- Pölkki T, Korhonen A, Axelin A, Saarela T, Laukkala H. Development and preliminary validation of the Neonatal Infant Acute Pain Assessment Scale (NIAPAS). Int J Nurs Stud. 2014 Dec;51(12):1585–94.
- Edwards DK, Hilton SV, Merritt TA, Hallman M, Mannino F, Boynton BR. Respiratory distress syndrome treated with human surfactant: radiographic findings. Radiology. 1985 Nov;157(2):329–34.
- Kallio M, Koskela U, Peltoniemi O, Kontiokari T, Pokka T, Suo-Palosaari M, et al. Neurally adjusted ventilatory assist (NAVA) in preterm newborn infants with respiratory distress syndrome-a randomized controlled trial. Eur J Pediatr. 2016 Sep;175(9):1175–83.
- Minocchieri S, Berry CA, Pillow JJ; CureNeb Study Team. Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2019 May;104(3):F313–9.
- Dargaville PA, Gerber A, Johansson S, De Paoli AG, Kamlin CO, Orsini F, et al.; Australian and New Zealand Neonatal Network. Incidence and Outcome of CPAP Failure in Preterm Infants. Pediatrics. 2016 Jul;138(1):e20153985.
Article / Publication Details
Received: May 14, 2019
Accepted: July 24, 2019
Published online: September 05, 2019
Issue release date: November 2019
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2
ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)
For additional information: https://www.karger.com/NEO
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
